Display options
Cite
Garrido-Suárez BB, Garrido G, Castro-Labrada M, et al. Anti-allodynic Effect of Mangiferin in Rats With Chronic Post-ischemia Pain: A Model of Complex Regional Pain Syndrome Type I. Front Pharmacol. 2018;9:1119doi: 10.3389/fphar.2018.01119.
Garrido-Suárez, B. B., Garrido, G., Castro-Labrada, M., Pardo-Ruíz, Z., Bellma Menéndez, A., Spencer, E., Godoy-Figueiredo, J., Ferreira, S. H., & Delgado-Hernández, R. (2018). Anti-allodynic Effect of Mangiferin in Rats With Chronic Post-ischemia Pain: A Model of Complex Regional Pain Syndrome Type I. Frontiers in pharmacology, 91119. https://doi.org/10.3389/fphar.2018.01119
Garrido-Suárez, Bárbara B, et al. "Anti-allodynic Effect of Mangiferin in Rats With Chronic Post-ischemia Pain: A Model of Complex Regional Pain Syndrome Type I." Frontiers in pharmacology vol. 9 (2018): 1119. doi: https://doi.org/10.3389/fphar.2018.01119
Garrido-Suárez BB, Garrido G, Castro-Labrada M, Pardo-Ruíz Z, Bellma Menéndez A, Spencer E, Godoy-Figueiredo J, Ferreira SH, Delgado-Hernández R. Anti-allodynic Effect of Mangiferin in Rats With Chronic Post-ischemia Pain: A Model of Complex Regional Pain Syndrome Type I. Front Pharmacol. 2018 Oct 02;9:1119. doi: 10.3389/fphar.2018.01119. eCollection 2018. PMID: 30333751; PMCID: PMC6176059.
Copy Download .nbib Format: NLM
Share it on

Front Pharmacol. 2018 Oct 02;9:1119. doi: 10.3389/fphar.2018.01119. eCollection 2018.

Anti-allodynic Effect of Mangiferin in Rats With Chronic Post-ischemia Pain: A Model of Complex Regional Pain Syndrome Type I.

Frontiers in pharmacology

Bárbara B Garrido-Suárez, Gabino Garrido, Marian Castro-Labrada, Zenia Pardo-Ruíz, Addis Bellma Menéndez, Evelyn Spencer, Jozi Godoy-Figueiredo, Sergio H Ferreira, René Delgado-Hernández

Affiliations

  1. Laboratorio de Farmacología y Toxicología, Centro de Investigación y Desarrollo de Medicamentos, Havana, Cuba.
  2. Departamento de Ciencias Farmacéuticas, Facultad de Ciencias, Universidad Católica del Norte, Antofagasta, Chile.
  3. Department of Pharmacology, Faculty of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, Brazil.
  4. Centro de Estudio para las Investigaciones y Evaluaciones Biológicas, Instituto de Farmacia y Alimentos, Universidad de La Habana, Havana, Cuba.

PMID: 30333751 PMCID: PMC6176059 DOI: 10.3389/fphar.2018.01119

Abstract

The present study reproduces chronic post-ischemia pain (CPIP), a model of complex regional pain syndrome type I (CRPS-I), in rats to examine the possible transient and long-term anti-allodynic effect of mangiferin (MG); as well as its potential beneficial interactions with some standard analgesic drugs and sympathetic-mediated vasoconstriction and vasodilator agents during the earlier stage of the pathology. A single dose of MG (50 and 100 mg/kg, p.o.) decreased mechanical allodynia 72 h post-ischemia-reperfusion (I/R). MG 100 mg/kg, i.p. (pre- vs. post-drug) increased von Frey thresholds in a yohimbine and naloxone-sensitive manner. Sub-effective doses of morphine, amitriptyline, prazosin, clonidine and a NO donor, SIN-1, in the presence of MG were found to be significantly anti-allodynic. A long-term anti-allodynic effect at 7 and 13 days post-I/R after repeated oral doses of MG (50 and 100 mg/kg) was also observed. Further, MG decreased spinal and muscle interleukin-1β concentration and restored muscle redox status. These results indicate that MG has a transient and long-term anti-allodynic effect in CPIP rats that appears to be at least partially attributable to the opioid and α

Keywords: adrenergic receptor; chronic post-ischemia pain; complex regional pain syndrome; mangiferin; sympathetically maintained pain

References

  1. Pain. 2010 Aug;150(2):268-74 - PubMed
  2. Pain. 2005 Aug;116(3):213-9 - PubMed
  3. Pain Res Manag. 2017;2017:7394626 - PubMed
  4. Cardiovasc Surg. 2002 Dec;10(6):620-30 - PubMed
  5. Int Immunopharmacol. 2002 May;2(6):797-806 - PubMed
  6. Clin Sci (Lond). 2002 Oct;103(4):409-15 - PubMed
  7. Eur J Pharmacol. 2004 Sep 24;499(3):297-305 - PubMed
  8. Exp Ther Med. 2014 Feb;7(2):508-512 - PubMed
  9. Clin Exp Pharmacol Physiol. 2016 Mar;43(3):355-9 - PubMed
  10. J Pain. 2009 Nov;10(11):1161-9 - PubMed
  11. PLoS One. 2015 Jul 21;10(7):e0132497 - PubMed
  12. BMC Musculoskelet Disord. 2008 Oct 20;9:143 - PubMed
  13. J Neurosci Methods. 1994 Jul;53(1):55-63 - PubMed
  14. Immunol Lett. 2004 Feb 15;91(2-3):147-54 - PubMed
  15. Eur J Pharmacol. 2013 Sep 15;716(1-3):2-7 - PubMed
  16. Free Radic Biol Med. 2011 Sep 1;51(5):951-66 - PubMed
  17. BMC Musculoskelet Disord. 2009 Sep 23;10:116 - PubMed
  18. Nitric Oxide. 2011 Oct 30;25(3):243-54 - PubMed
  19. Toxicol Appl Pharmacol. 2012 Apr 1;260(1):35-47 - PubMed
  20. Pain. 2010 Oct;151(1):174-83 - PubMed
  21. Anal Biochem. 1968 Oct 24;25(1):192-205 - PubMed
  22. Pain. 2008 Jul 31;137(3):640-51 - PubMed
  23. J Agric Food Chem. 2002 Feb 13;50(4):762-6 - PubMed
  24. Eura Medicophys. 2006 Jun;42(2):103-11 - PubMed
  25. Biol Pharm Bull. 2005 Apr;28(4):596-600 - PubMed
  26. Pharmacol Biochem Behav. 2016 Nov - Dec;150-151:190-197 - PubMed
  27. Anesth Analg. 2005 Oct;101(4):1063-4, table of contents - PubMed
  28. PLoS One. 2013 Aug 08;8(8):e71759 - PubMed
  29. Pain. 2006 Feb;120(3):235-43 - PubMed
  30. Lancet. 1999 Dec 11;354(9195):2025-8 - PubMed
  31. Eur J Pharmacol. 2008 Mar 31;583(1):97-102 - PubMed
  32. Eur J Pharmacol. 1991 Jan 3;192(1):133-9 - PubMed
  33. Forsch Komplementmed. 2011;18(6):345-50 - PubMed
  34. Pharmacol Biochem Behav. 2014 Sep;124:311-9 - PubMed
  35. BMC Musculoskelet Disord. 2006 Nov 30;7:91 - PubMed
  36. Chem Res Toxicol. 1998 Oct;11(10):1184-94 - PubMed
  37. Cardiovasc Drug Rev. 2004 Summer;22(2):91-102 - PubMed
  38. Neuropharmacology. 2007 Mar;52(3):708-15 - PubMed
  39. Pain. 2008 Aug 15;138(1):226-32 - PubMed
  40. Heart Fail Rev. 2003 Jan;8(1):107-15 - PubMed
  41. Pain Med. 2010 Aug;11(8):1224-38 - PubMed
  42. J Pain. 2008 May;9(5):423-33 - PubMed
  43. Molecules. 2010 Dec 09;15(12):9035-45 - PubMed
  44. Lancet Neurol. 2003 Nov;2(11):687-97 - PubMed
  45. Pain. 2004 Nov;112(1-2):94-105 - PubMed
  46. Pharmacol Biochem Behav. 2013 Sep;110:19-26 - PubMed
  47. Metabolism. 2015 Mar;64(3):428-37 - PubMed
  48. Pharmacol Res. 2008 Jun;57(6):419-25 - PubMed
  49. Pain. 2010 Nov;151(2):251-6 - PubMed
  50. Neurosci Lett. 2008 Jun 6;437(3):199-202 - PubMed
  51. Pharmacol Res. 2004 Aug;50(2):165-72 - PubMed
  52. ACS Chem Neurosci. 2015 Nov 18;6(11):1789-93 - PubMed
  53. Pharmacol Rev. 1991 Jun;43(2):109-42 - PubMed
  54. Lancet Neurol. 2015 Feb;14(2):162-73 - PubMed
  55. Pharmacol Res. 2008 Jan;57(1):79-86 - PubMed
  56. Pain. 2012 Jun;153(6):1187-92 - PubMed
  57. Pain. 2003 Apr;102(3):297-307 - PubMed
  58. Curr Ther Res Clin Exp. 2011 Oct;72(5):216-27 - PubMed
  59. Methods Mol Biol. 2000;99:15-24 - PubMed
  60. Eur J Pharmacol. 2010 Jun 10;635(1-3):124-8 - PubMed
  61. Pain. 2007 Nov;132(1-2):195-205 - PubMed
  62. Pain. 2016 Oct;157(10):2366-74 - PubMed
  63. Anesthesiology. 1991 Apr;74(4):691-8 - PubMed
  64. J Pharm Pharmacol. 2006 Mar;58(3):385-92 - PubMed
  65. Pain. 2006 May;122(1-2):17-21 - PubMed
  66. Brain Behav Immun. 2007 Jul;21(5):668-76 - PubMed
  67. Int J Med Sci. 2017 Jan 15;14(1):97-101 - PubMed
  68. Acta Physiol Scand. 1986 Jan;126(1):121-33 - PubMed
  69. Anesth Analg. 2014 Apr;118(4):830-40 - PubMed
  70. Pain. 2002 Jan;95(1-2):119-24 - PubMed
  71. Anal Biochem. 1976 May 7;72:248-54 - PubMed
  72. J Biol Chem. 1951 Nov;193(1):265-75 - PubMed
  73. Mol Pain. 2008 Oct 28;4:49 - PubMed
  74. J Pain. 2013 Jan;14(1):66-78 - PubMed
  75. Cell Calcium. 2009 Apr;45(4):358-68 - PubMed
  76. Int Immunopharmacol. 2004 Jun;4(6):763-78 - PubMed
  77. Pain. 2015 Apr;156 Suppl 1:S94-103 - PubMed
  78. J Pain Res. 2017 Jul 31;10:1811-1819 - PubMed
  79. Biofactors. 2016 Sep 10;42(5):475-491 - PubMed
  80. Eur J Pharmacol. 2013 Oct 15;718(1-3):393-400 - PubMed
  81. Curr Eye Res. 2016 Jun;41(6):844-55 - PubMed

Publication Types